Morgan Stanley Axsome Therapeutics, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 410,150 shares of AXSM stock, worth $38.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

410,150

Previous 321,981 27.38%

Holding current value

$38.2 Million

Previous $25.9 Million 42.18%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$78.93 - $95.84 $6.96 Million - $8.45 Million	88,169 Added 27.38%	410,150 $36.9 Million
Q2 2024 Oct 17, 2024	SELL	$65.72 - $80.5 $40.9 Million - $50.1 Million	-621,902 Reduced 65.89%	321,981 $25.9 Million
Q2 2024 Aug 14, 2024	SELL	$65.72 - $80.5 $40.9 Million - $50.1 Million	-621,902 Reduced 65.89%	321,981 $25.9 Million
Q1 2024 Oct 17, 2024	BUY	$69.39 - $97.64 $43.2 Million - $60.7 Million	621,902 Added 193.15%	943,883 $75.3 Million
Q1 2024 Aug 16, 2024	BUY	$69.39 - $97.64 $22.5 Million - $31.7 Million	324,504 Added 52.39%	943,883 $75.3 Million
Q1 2024 May 15, 2024	BUY	$69.39 - $97.64 $22.5 Million - $31.7 Million	324,504 Added 52.39%	943,883 $75.3 Million
Q4 2023 Aug 16, 2024	BUY	$57.42 - $83.61 $17.1 Million - $24.9 Million	297,398 Added 92.37%	619,379 $49.3 Million
Q4 2023 Feb 13, 2024	BUY	$57.42 - $83.61 $18.4 Million - $26.8 Million	320,958 Added 107.55%	619,379 $49.3 Million
Q3 2023 Nov 15, 2023	SELL	$69.25 - $82.21 $1.72 Million - $2.05 Million	-24,896 Reduced 7.7%	298,421 $20.9 Million
Q2 2023 Aug 14, 2023	SELL	$58.41 - $90.35 $7.27 Million - $11.2 Million	-124,455 Reduced 27.79%	323,317 $23.2 Million
Q1 2023 May 15, 2023	SELL	$58.39 - $75.0 $1.72 Million - $2.21 Million	-29,484 Reduced 6.18%	447,772 $27.6 Million
Q4 2022 Feb 14, 2023	SELL	$39.94 - $79.72 $4.88 Million - $9.75 Million	-122,275 Reduced 20.4%	477,256 $36.8 Million
Q3 2022 Nov 14, 2022	BUY	$36.06 - $69.85 $7.48 Million - $14.5 Million	207,545 Added 52.95%	599,531 $26.8 Million
Q2 2022 Oct 27, 2022	BUY	$21.74 - $46.75 $3.5 Million - $7.53 Million	161,074 Added 69.76%	391,986 $15 Million
Q2 2022 Aug 15, 2022	BUY	$21.74 - $46.75 $3.5 Million - $7.53 Million	161,074 Added 69.76%	391,986 $15 Million
Q1 2022 Oct 27, 2022	SELL	$23.7 - $41.39 $3.82 Million - $6.67 Million	-161,074 Reduced 41.09%	230,912 $9.56 Million
Q1 2022 May 13, 2022	BUY	$23.7 - $41.39 $1.28 Million - $2.24 Million	54,016 Added 30.54%	230,912 $9.56 Million
Q4 2021 Feb 14, 2022	SELL	$30.7 - $43.36 $5.8 Million - $8.2 Million	-189,073 Reduced 51.66%	176,896 $6.68 Million
Q3 2021 Nov 15, 2021	BUY	$19.91 - $68.26 $7.29 Million - $25 Million	365,969 New	365,969 $12.1 Million

Others Institutions Holding AXSM

# of Institutions

326

Shares Held

37.7M

Call Options Held

912K

Put Options Held

855K

View Full List

About Axsome Therapeutics, Inc.

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $3.99B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

More about AXSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account